Patnaik, Amita <br/><br/>
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jun 2013 
 - 1499-506 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-013-2149-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Camptothecin--administration & dosage<br/>Data Interpretation, Statistical<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Irinotecan<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Polyethylene Glycols--administration & dosage<br/>Prodrugs--administration & dosage<br/>Treatment Outcome